LNPs as delivery platform of Rituximab for SMZL

Splenic Marginal Zone Lymphoma (SMZL) is a low-grade B-cell non-Hodgkin lymphoma from which patients may suffer anemia, autoimmune disorder and splenomegaly respectively. Due to its chronic nature, it has been increasingly hard to identify and treat effectively. The study establishes an SMZL mouse model and explores the potential of enhancing Rituximab treatment using Lipid Nanoparticles (LNPs). Designed experiment includes how to establish the NFS.N mice model, characterization of the disease on mice and recovery standard of mice. First, SMZL mice model is establish followed by histology and immunocytochemistry investigation which looks directly at the mices lesion. Then flow cytology is carried out which looks at the expression level of IgM, IgK, CD23, CD45 etc., before bone marrow infiltration is carried out. A controlled experiment of three groups of mice is designed, including mice treated with conventional Rituximab, delivery with LNPs and delivering empty LNPs, respectively. The effect of LNPs on treating mice SMZL is investigated. And some expected results and analysis methods were also discussed alongside with recovery standard. This experiment aims to provide theoretical support to the development of more effective and targeted therapies for this specific type of lymphoma. However, this is only an design rigorous experimentation strengthens the scientific validity of these findings.